ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Valuation Check After EU Approval Of First Disease Modifying Therapy For Type 1 Diabetes
The latest movement in Sanofi (ENXTPA:SAN) has been influenced by a European Commission approval for Teizeild, the first EU-cleared disease-modifying therapy intended to delay stage 3 type 1 diabetes in eligible patients.
See our latest analysis for Sanofi.
Despite the recent Teizeild approval and other pipeline updates, Sanofi’s share price, which last closed at €82.41, has moved only modestly, with a near flat year to date share price return and a 1 year total shareholder return decline...